@import url("/css/styles.css");
Avlar BioVentures
About Avlar
Management
Active Management
Leaders in Life Sciences
Cambridge Cluster
Presentations
Testimonials
Portfolio Companies
Quoted Companies
CeNeS
York Pharma plc
Intercytex Ltd
Unquoted Companies
Amura Ltd
Aitua Ltd
CellCentric Ltd
De Novo Pharmaceuticals
ImmunoBiology Ltd
Medical Device Innovation
Proteom
Purely Proteins
Sold Companies
Paradigm Therapeutics
Cozart plc
Sterix Limited
Cambridge Biotechnology L
Sangamo BioSciences
Portfolio News
For Investors
The Funds
Investment Process
For Entrepreneurs
Investment criteria
Business Plan Submission
Our Investors
Preferred Advisors
Opportunities
Contact Us
How to find us
You are here:
Homepage
>
For Investors
>
Investment Process
Quoted Portfolio Companies
CeNeS
York Pharma plc
Intercytex Ltd
Unquoted Portfolio Companies
Amura Ltd
Aitua Ltd
CellCentric Ltd
De Novo Pharmaceuticals
ImmunoBiology Ltd
Medical Device Innovation
Proteom
Purely Proteins
Sold Companies
Paradigm Therapeutics
Cozart plc
Sterix Limited
Cambridge Biotechnology L
Sangamo BioSciences
Saturday, May 10, 2008
Investment Process
Investment Strategy
Click here to view larger image.
Investment Process
Click here to view larger image.
Portfolio News
18 April 2008
Intercytex plc: funding award from US Government
10 April 2008
Recommended Acquisition of CENES PHARMACEUTICALS PLC by PAION AG
10 April 2008
CeNeS Pharmaceuticals plc proposed acquisition by PAION AG
All Portfolio News
News Archive
2004
News Archive
Weather in Cambridge
Temp: N/A ºF
Last Updated: N/A
Our Investors
3i
Access Capital Partners
Astellas Venture Capital
Avlar management
BTG
Cambridge University
Coller Capital
European Investment Fund
Lloyds TSB DC
Lexington Partners Inc
Preferred Advisors
Morrison & Foerster MNP
Opportunities
CEOs with relevant experience for start-up / early stage Life Science companies.